Genscript Bio Gets Booster from Subsidiary’s New Cancer Drug
The company’s Legend Biotech unit has found recent success with Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, which earned $134 million in its first nine months on the marketKey…
FAST NEWS: Legend Biotech Plans $250 Million ADS Public Offering
The latest: Genscript Biotech Corp. (1548.HK) announced its New York-listed subsidiary, Legend Biotech Corp. (LEGN.US), plans to conduct a public offering of $250 million worth of American Depository Shares (ADS).…
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
Company expects to lose up to $519 million last year, but its fortunes may improve after its Legend Biotech unit received FDA approval this week for a new CAR-T cell…
